View clinical trials related to Other.
Filter by:A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
This phase Ib/II trial studies the side effects and best dose of copanlisib when given together with trastuzumab and pertuzumab and to see how well they work after induction treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab) could shrink the cancer or stabilize it for longer duration as compared to the usual treatment alone.
The purpose of the study is to evaluate the group-based intervention "Starting the Conversation" as a webinar in Germany. Feasibility and efficacy of the program will be tested in a pilot randomized-controlled trial (RCT).
Primary Objective: The primary objective of this study is to assess the tolerability and safety of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients. Secondary Objectives: The secondary objectives of this study are to assess PK and exploratory efficacy and quality of life of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.
This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy, cisplatin, and cetuximab may work better in treating patients with HPV positive, KRAS-variant oropharyngeal squamous cell carcinoma compared to radiation therapy and cisplatin alone.
A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome
Impaired olfaction is one of the major complaints of patients with nasosinus polyposis, with nasal obstruction. In case of failure of medical treatment for patients with polyposis nasosinusal, they may use endoscopic surgery nasosinusal. Before surgery, 73% are hyposmic or anosmic, compared to 43% after surgery. Persistence of hyposmia or anosmia despite the removal of polyps can be explained by mechanisms inflammatory in the mucous membrane of the olfactory cleft. In addition, studies in mice have shown a degeneration of primary olfactory neurons at the level of the olfactory mucosa in connection with directly with TNF alpha, a pro-inflammatory molecule.
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
This project will serve adolescents from low-income and historically underserved communities through expansion of existing after-school programs. Adolescents from these communities tend to have slower academic progression and higher high school dropout rates. Extracurricular activities, including informal education through after-school programming, have been suggested to improve these rates and increase college enrollment by supporting traditional classroom-based education. The proposed project aims to educate high school-aged adolescents in food, agriculture, natural resources, and human (FANH) sciences through informal food literacy education. The project also includes a two-tiered cross-age teaching model, allowing for adolescents to be educated by college interns and to become educators for younger youth. Existing curricula, that encompass FANH sciences, will be utilized at each stage of the project. The purpose of the project is not only to educate adolescents in FANH sciences, but also to advance their motivation and efficacy for graduating high school, attending college, and majoring in FANH sciences. The project aims to accomplish these objectives through empowering adolescents to obtain knowledge, skills, and excitement for food literacy. As this model has not been utilized previously, this project will produce a best practices guide for implementing the existing curricula within a two-tiered cross-age teaching model. Additionally, the college internship and mentoring program created through this project will be continued at the initial sites and expanded to other communities. This will allow for a sustainable approach to educating adolescents in FANH sciences and providing mentorship that encourages future enrollment in college.